Drug makers race to release drugs that fight blood clots
NEW YORK Johnson & Johnson, Bayer and Boehringer Ingelheim may rake in huge profits with novel drugs for fighting blood clots, according to Bloomberg News.
Research data reported at the annual meeting of the American Society of Hematology in San Francisco found that the new drugs were more effective than Bristol-Myers Squibb’s Coumadin (warfarin). They include Boehringer Ingelheim’s Pradaxa (dabigatran etexilate) and Xarelto (rivaroxaban), made by Bayer and J&J.
FDA approves Galderma’s Epiduo Gel treatment for acne
ROCKVILLE, Md. The Food and Drug Administration has approved a new acne treatment by Galderma Laboratories, the agency announced Wednesday.
The treatment, Epiduo Gel, is known generically as adapalene and benzoyl peroxide and is used to treat acne vulgaris in patients aged 12 and older.
FDA records indicate the agency approved it Monday.
Galderma, based in Lausanne, Switzerland, had not made a statement about the approval at midday Wednesday.
Wyeth announces lay-offs at operations in Puerto Rico
SAN JUAN, Puerto Rico More than 200 Wyeth Pharmaceuticals employees in Puerto Rico will lose their jobs between the end of the year and February, according to the Associated Press.
The drug maker said it would lay off 276 workers as part of a restructuring plan and drop in demand. The company employs about 3,000 people in the territory.
A spokeswoman for the company said the availability of generics reduced demand for the anti-anxiety drug Effexor (venlafaxine hydrochloride) and the acid reflux disease drug Protonix (pantoprazole sodium).